Skip to main content
. 2024 May 7;73(7):116. doi: 10.1007/s00262-024-03697-3

Fig. 3.

Fig. 3

Adjusted IPTW OS and rwOS in patients with resected stage III melanoma (per AJCC-8) who received adjuvant nivolumab in the CheckMate 238 and real-world cohorts, respectively. AJCC-8 American Joint Committee on Cancer, Cancer Staging Manual, eighth edition, CI Confidence interval, HR Hazard ratio, IPTW Inverse probability of treatment weighting, OS Overall survival, rwOS Real-world overall survival